These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 25041362)

  • 1. Rational design of CXCR4 specific antibodies with elongated CDRs.
    Liu T; Liu Y; Wang Y; Hull M; Schultz PG; Wang F
    J Am Chem Soc; 2014 Jul; 136(30):10557-60. PubMed ID: 25041362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel heavy domain antibody library with functionally optimized complementarity determining regions.
    Mandrup OA; Friis NA; Lykkemark S; Just J; Kristensen P
    PLoS One; 2013; 8(10):e76834. PubMed ID: 24116173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diversity in the Cow Ultralong CDR H3 Antibody Repertoire.
    Haakenson JK; Huang R; Smider VV
    Front Immunol; 2018; 9():1262. PubMed ID: 29915599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rational design of a humanized glucagon-like peptide-1 receptor agonist antibody.
    Zhang Y; Zou H; Wang Y; Caballero D; Gonzalez J; Chao E; Welzel G; Shen W; Wang D; Schultz PG; Wang F
    Angew Chem Int Ed Engl; 2015 Feb; 54(7):2126-30. PubMed ID: 25556336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimizing the immunogenicity of antibodies for clinical application.
    Gonzales NR; De Pascalis R; Schlom J; Kashmiri SV
    Tumour Biol; 2005; 26(1):31-43. PubMed ID: 15741769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolation of antigen-specific, disulphide-rich knob domain peptides from bovine antibodies.
    Macpherson A; Scott-Tucker A; Spiliotopoulos A; Simpson C; Staniforth J; Hold A; Snowden J; Manning L; van den Elsen J; Lawson ADG
    PLoS Biol; 2020 Sep; 18(9):e3000821. PubMed ID: 32886672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Grabbing the Bull by Both Horns: Bovine Ultralong CDR-H3 Paratopes Enable Engineering of 'Almost Natural' Common Light Chain Bispecific Antibodies Suitable For Effector Cell Redirection.
    Klewinghaus D; Pekar L; Arras P; Krah S; Valldorf B; Kolmar H; Zielonka S
    Front Immunol; 2021; 12():801368. PubMed ID: 35087526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ligand selectivity of a synthetic CXCR4 mimetic peptide.
    Groß A; Brox R; Damm D; Tschammer N; Schmidt B; Eichler J
    Bioorg Med Chem; 2015 Jul; 23(14):4050-5. PubMed ID: 25801155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The critical role of arginine residues in the binding of human monoclonal antibodies to cardiolipin.
    Giles I; Lambrianides N; Latchman D; Chen P; Chukwuocha R; Isenberg D; Rahman A
    Arthritis Res Ther; 2005; 7(1):R47-56. PubMed ID: 15642142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A universal combinatorial design of antibody framework to graft distinct CDR sequences: a bioinformatics approach.
    Haidar JN; Yuan QA; Zeng L; Snavely M; Luna X; Zhang H; Zhu W; Ludwig DL; Zhu Z
    Proteins; 2012 Mar; 80(3):896-912. PubMed ID: 22180101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. De novo design of antibody complementarity determining regions binding a FLAG tetra-peptide.
    Entzminger KC; Hyun JM; Pantazes RJ; Patterson-Orazem AC; Qerqez AN; Frye ZP; Hughes RA; Ellington AD; Lieberman RL; Maranas CD; Maynard JA
    Sci Rep; 2017 Aug; 7(1):10295. PubMed ID: 28860479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding differences between synthetic and natural antibodies can help improve antibody engineering.
    Burkovitz A; Ofran Y
    MAbs; 2016; 8(2):278-87. PubMed ID: 26652053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A germline knowledge based computational approach for determining antibody complementarity determining regions.
    Zhao S; Lu J
    Mol Immunol; 2010 Jan; 47(4):694-700. PubMed ID: 19939452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of positively charged residues in CXCR4 recognition probed with synthetic peptides.
    Luo Z; Zhou N; Luo J; Hall JW; Huang Z
    Biochem Biophys Res Commun; 1999 Oct; 263(3):691-5. PubMed ID: 10512741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rational design of antibody protease inhibitors.
    Liu T; Fu G; Luo X; Liu Y; Wang Y; Wang RE; Schultz PG; Wang F
    J Am Chem Soc; 2015 Apr; 137(12):4042-5. PubMed ID: 25775396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural Diversity of Ultralong CDRH3s in Seven Bovine Antibody Heavy Chains.
    Dong J; Finn JA; Larsen PA; Smith TPL; Crowe JE
    Front Immunol; 2019; 10():558. PubMed ID: 30967877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Analysis of the CDR Loops of Antigen Receptors.
    Wong WK; Leem J; Deane CM
    Front Immunol; 2019; 10():2454. PubMed ID: 31681328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A human synthetic combinatorial library of arrayable single-chain antibodies based on shuffling in vivo formed CDRs into general framework regions.
    Azriel-Rosenfeld R; Valensi M; Benhar I
    J Mol Biol; 2004 Jan; 335(1):177-92. PubMed ID: 14659749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Computational design of protein antigens that interact with the CDR H3 loop of HIV broadly neutralizing antibody 2F5.
    Azoitei ML; Ban YA; Kalyuzhny O; Guenaga J; Schroeter A; Porter J; Wyatt R; Schief WR
    Proteins; 2014 Oct; 82(10):2770-82. PubMed ID: 25043744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing CDRH3 diversity captured from secondary lymphoid organs for the generation of recombinant human antibodies.
    Venet S; Kosco-Vilbois M; Fischer N
    MAbs; 2013; 5(5):690-8. PubMed ID: 23924800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.